Goldman Sachs Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $35

Benzinga · 1d ago
Goldman Sachs analyst Matt Dellatorre maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $31 to $35.